Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 – 2013

Bibliography

• Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of Syk protein-tyrosine kinase. J Biochem 2001;130(2):177-86
   PubMed Web of Science ®Google Scholar
• Wong BR, Grossbard EB, Payan DG, Masuda ES. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 2004;13(7):743-62
   PubMed Web of Science ®Google Scholar
• Tohyama Y, Yamamura H. Protein tyrosine kinase, syk: a key player in phagocytic cells. J Biochem 2009;145(3):267-73
   PubMed Web of Science ®Google Scholar
• Siraganian RP, Zhang J, Suzuki K, Sada K. Protein tyrosine kinase Syk in mast cell signaling. Mol Immunol 2002;38(16-18):1229-33
   PubMed Web of Science ®Google Scholar
• Jakus Z, Simon E, Balázs B, Mócsai A. Genetic deficiency of Syk protects mice from autoantibody-induced arthritis. Arthritis Rheum 2010;62(7):1899-910
   PubMed Web of Science ®Google Scholar
• Wex E, Bouyssou T, Duechs MJ, et al. Induced Syk deletion leads to suppressed allergic responses but has no effect on neutrophil or monocyte migration in vivo. Eur J Immunol 2011;41(11):3208-18
   PubMed Web of Science ®Google Scholar
• Ciebiada M, Kasztalska K, Gorska-Ciebiada M, Górski P. ZAP70 expression in regulatory T cells in allergic rhinitis: effect of immunotherapy. Clin Exp Allergy 2013;43(7):752-61
   PubMed Web of Science ®Google Scholar
• Latour S, Veillette A. Proximal protein tyrosine kinases in immunoreceptor signaling. Curr Opin Immunol 2001;13:299-306
   PubMed Web of Science ®Google Scholar
• Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010;10(6):387-402
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-47
   PubMed Web of Science ®Google Scholar
• Ruzza P, Biondi B, Calderan A. Therapeutic prospect of Syk inhibitors. Expert Opin Ther Pat 2009;19(10):1361-76
   PubMed Web of Science ®Google Scholar
• Riccaboni M, Bianchi I, Petrillo P. Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov Today 2010;15(13-14):517-30
   PubMed Web of Science ®Google Scholar
• Scott DL. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis. Drugs 2011;71(9):1121-32
   PubMed Web of Science ®Google Scholar
• Nijjar JS, Tindell A, McInnes IB, Siebert S. Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2013;52(9):1556-62
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Genovese MC, et al. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. J Rheumatol 2013;40(4):369-78
   PubMed Web of Science ®Google Scholar
• AstraZeneca plc. AstraZeneca announces top-line results from Phase III OSKIRA Trials of FOSTAMATINIB and decision not to proceed with regulatory filings. Press Release 4 June 2013
   Google Scholar
• Efremov DG, Laurenti L. The Syk kinase as a therapeutic target in leukemia and lymphoma. Expert Opin Investig Drugs 2011;20(5):623-36
   PubMed Web of Science ®Google Scholar
• Herman SE, Barr PM, McAuley EM, et al. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia 2013;27(8):1769-73
   PubMed Web of Science ®Google Scholar
• Coffey G, DeGuzman F, Inagaki M, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther 2012;340(2):350-9
   PubMed Web of Science ®Google Scholar
• Vertex Pharmaceuticals, Inc. Thiazole compounds useful as inhibitors of protein kinases. WO2002096905; 2002
   Google Scholar
• Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses. WO2003063794; 2003
   Google Scholar
• Moore WJ, Richard D, Thorarensen A. An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola. Expert Opin Ther Pat 2010;20(12):1703-22
   PubMed Web of Science ®Google Scholar
• Rigel Pharmaceuticals, Inc. 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses. WO 2011130390; 2011
   Google Scholar
• Rigel Pharmaceuticals, Inc. 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses. WO 2011130390; 2011
   Google Scholar
• Rigel Pharmaceuticals, Inc. Synthesis of N4-(2,2-dimethyl-4-[(dihydrogenphosphonoxy]-3-oxo-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5,-trimethoxyphenyl)-2,4-pyrimidinediamine disodium salt. WO2011002999; 2011
   Google Scholar
• Rigel Pharmaceuticals, Inc. Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses. WO2011009075; 2011
   Google Scholar
• Rigel Pharmaceuticals, Inc. 2,4-substituted pyrimidinediamines for use in discoid lupus. WO2012122452; 2012
   Google Scholar
• Rigel Pharmaceuticals, Inc. Topical formulation for administering a compound. WO2013086196; 2013
   Google Scholar
• Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway. WO2008079907; 2008
   Google Scholar
• AstraZeneca AB. New (trimethoxyphenylamino)pyrimidinyl formulations. WO2013014454; 2013
   Google Scholar
• US Government. Compositions and methods for treating or preventing lupus. WO2012071042; 2012
   Google Scholar
• Charles N, Rivera J. Basophils and autoreactive IgE in the pathogenesis of systemic lupus erythematosus. Curr Allergy Asthma Rep 2011;11(5):378-87
   PubMed Web of Science ®Google Scholar
• Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide. WO2012044936; 2012
   Google Scholar
• Portola Pharmaceuticals, Inc. Combinations of 4-(3-(2H-1,2,3-triazo-2-yl) phenylamino)-2-((1R,2S)-2-aminocyclohexylamino) pyrimidine-5-carboxamide and fludarabine. WO2012045010; 2012
   Google Scholar
• Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine. WO2012045020; 2012
   Google Scholar
• Portola Pharmaceuticals, Inc. Preparation of diaminopyrimidinylcarboxamide derivatives for use as SYK and JAK kinases inhibitors. WO2009145856; 2009
   Google Scholar
• Portola Pharmaceuticals, Inc. Oxypyrimidines as Syk modulators. WO2012061415; 2012
   Google Scholar
• Portola Pharmaceuticals, Inc. Selective kinase inhibitors. WO2013078468; 2013
   Google Scholar
• Merck Sharp & Dohme Corp., Merck Canada, Inc. Aminopyrimidines as Syk inhibitors. WO2011075515; 2011
   Google Scholar
• Merck Sharp & Dohme Corp., Merck Canada, Inc. Aminopyrimidines as Syk inhibitors. WO2011075517; 2011
   Google Scholar
• Merck Sharp & Dohme Corp., Merck Canada, Inc. Aminopyrimidines as Syk inhibitors. WO2011075560; 2011
   Google Scholar
• Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors. WO2012154519; 2012
   Google Scholar
• Boehringer Ingelheim International Gmbh. Substituted pyridinyl-pyrimidines and their use as medicaments. WO2012101013; 2012
   Google Scholar
• Boehringer Ingelheim International Gmbh. Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments. WO2013156608; 2013
   Google Scholar
• Glaxo Wellcome plc. Pyrimidinecarboxamide derivatives as inhibitors of syk kinase. WO2010097248; 2010
   Google Scholar
• Liddle J, Atkinson FL, Barker MD, et al. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor. Bioorg Med Chem Lett 2011;21(20):6188-94
   PubMed Web of Science ®Google Scholar
• Portola Pharmaceuticals, Inc. Inhibitors of Syk protein kinase. WO2009136995; 2009
   Google Scholar
• Cellzome Ltd. Heterocyclylaminopyrimidines as kinase inhibitors. WO2010146133; 2010
   Google Scholar
• Auspex Pharmaceuticals, Inc. Trimethoxyphenyl inhibitors of tyrosine kinase. WO2011106248; 2011
   Google Scholar
• Genosco; Oscotec, Inc. Substituted pyrimidine compounds and their use as syk inhibitors. WO2013109882; 2013
   Google Scholar
• Lee EH, Chang SH, Hwang HJ, et al. A novel SYK selective inhibitor for the treatment of rheumatoid arthritis [abstract 437]. American College of Rheumatology Annual Meeting; 2011
   Google Scholar
• Alcon Research Ltd. Treatment for microbe-induced inflammatory responses in the eye. WO2013155381; 2013
   Google Scholar
• Origenis Gmbh. Novel kinase inhibitors. US20120329780; 2012
   Google Scholar
• Liao C, Hsu J, Kim Y, et al. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy. Arthritis Res Ther 2013;15:R146
   PubMed Web of Science ®Google Scholar
• Merck & Co, Inc. Bipyridylaminopyridines as syk inhibitors. WO2012154518; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors. WO2012154520; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors. WO2012151137; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors. WO2013052391; 2013
   Google Scholar
• Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (Syk) inhibitors. WO2013052393; 2013
   Google Scholar
• Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors. WO2013052394; 2013
   Google Scholar
• Fujifilm Corp. Novel nicotinamide derivatives or salts thereof. WO2012002577; 2012
   Google Scholar
• Fujifilm Corp. Novel nicotinamide derivatives or salts thereof. WO2013099041; 2012
   Google Scholar
• Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as syk modulators. WO2012061418; 2012
   Google Scholar
• Revotar Biopharmaceuticals AG. Lipase inhibitors for use for the treatment of obesity. WO2010043592; 2013
   Google Scholar
• Hoffmann-La Roche AG. Pyridazine amide compounds and their use as Syk inhibitors. WO2013104573; 2013
   Google Scholar
• Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors. WO2013078466; 2013
   Google Scholar
• Taiho Pharmaceutical Co Ltd. 1,2,4-triazine-6-carboxamide derivative. WO2013047813; 2013
   Google Scholar
• Novartis AG. Monocyclic heteroaryl cycloalkyldiamine derivatives. WO2013171690; 2013
   Google Scholar
• Almirall Prodesfarma SA. Pyridine and isoquinoline derivatives as syk- and jak-kinase inhibitors. WO2012041476; 2012
   Google Scholar
• Nippon Shinyaku Co Ltd. Pyridine derivative and medicinal agent. WO2012057262; 2012
   Google Scholar
• Yamamoto N, Takeshita K, Shichijo M, et al. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther 2003;306(3):1174-81
   PubMed Web of Science ®Google Scholar
• Penton PC, Wang X, Amatullah H, et al. Spleen tyrosine kinase inhibition attenuates airway hyperresponsiveness and pollution-induced enhanced airway response in a chronic mouse model of asthma. J Allergy Clin Immunol 2013;131(2):512-20
   PubMed Web of Science ®Google Scholar
• Burke RT, Meadows S, Loriaux MM, et al. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget 2013; In press
   PubMedGoogle Scholar
• E.g. F. Hoffmann-La Roche AG. Pyrrolopyrazine kinase inhibitors. WO2009106441; 2009
   Google Scholar
• F. Hoffmann-La Roche AG. Pyrrolo[2,3- b]pyrazine-7- carboxamide derivatives and their use as jak and syk inhibitors. WO2011144584; 2011
   Google Scholar
• F. Hoffmann-La Roche AG. Pyrrolopyrazine kinase inhibitors. WO2011144585; 2011
   Google Scholar
• F. Hoffmann-La Roche AG. Pyrrolopyrazine kinase inhibitors. WO2013030138; 2013
   Google Scholar
• Aventis Pharmaceuticals. WO2003065690; 2003
   Google Scholar
• Villaseñor AG, Kondru R, Ho H, et al. Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes. Chem Biol Drug Des 2009;73(4):466-70
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis. Improved chemical synthesis of diazaindoles by Chichibabin cyclization. WO2010107969; 2010
   Google Scholar
• Sanofi-Aventis. Crystalline forms. WO2010065690; 2010
   Google Scholar
• Sanofi-Aventis. Treatment for glomerulonephritis with 2-[4-(-7-ethyl-5H-pyrrolo[2,3-b]-pyrazin-6-yl)propan-2-ol. WO2010065571; 2010
   Google Scholar
• Sanofi-Aventis. A pyrrolopyrazin as Syk-kinase inhibitor. WO2008033798; 2010
   Google Scholar
• Gilead Connecticut, Inc. Imidazopyrazine Syk inhibitors. WO2010068257; 2010
   Google Scholar
• Gilead Connecticut, Inc. Imidazopyrazine Syk inhibitors. WO2010068258; 2010
   Google Scholar
• Hutchison Medipharma Ltd. Substituted pyridopyrazines as novel syk inhibitors. WO2012167423; 2012
   Google Scholar
• Hutchison Medipharma Ltd. Substituted pyridopyrazines as novel syk inhibitors. WO2012167733; 2012
   Google Scholar
• Glaxo Wellcome plc. Pyrido[3,4-b]pyrazine derivatives as syk inhibitors. WO2012123312; 2012
   Google Scholar
• Cai Y, Sun Z, Ren P, et al. HM-0523, a novel Syk inhibitor significantly ameliorates the severity of arthritis in rodents [abstract 474]. American College of Rheumatology Annual Meeting. 2013
   Google Scholar
• Merck Patent Gmbh. Triazolopyrazine derivatives. WO2012025186; 2012
   Google Scholar
• Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods. WO2009155551A1; 2009
   Google Scholar
• Galapagos NV. [1, 2, 4] triazolo [1, 5-a] pyridines as JAK inhibitors. WO2010010184A1; 2010
   Google Scholar
• Merck Patent Gmbh. 8-substituted 2 -amino – [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors. WO2013124026; 2013
   Google Scholar
• Merck Patent Gmbh. Triazolopyrazine derivatives. WO2013131609; 2013
   Google Scholar
• Boehringer Ingelheim International Gmbh. 4-Dimethylamino-Phenyl-Substituted Naphthyridines, and use thereof as medicaments. WO2010015518; 2010
   Google Scholar
• Boehringer Ingelheim International Gmbh. Substituted Naphthyridines, and use thereof as medicaments. WO2010015520; 2010
   Google Scholar
• Boehringer Ingelheim International Gmbh. Substituted naphthyridines and their use as Syk kinase inhibitors. WO2011092128; 2011
   Google Scholar
• Boehringer Ingelheim International Gmbh. Substituted quinolines and their use as medicaments. WO2013014060; 2013
   Google Scholar
• IRM LLC. 2, 7-naphthyridin-1-one derivatives as syk kinase inhibitors. WO2011014515; 2011
   Google Scholar
• Glaxo Wellcome plc. 7-(1H-Pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors. WO2011134971; 2011
   Google Scholar
• E Merck Patent Gmbh. Furopyridine derivatives. WO2012025187; 2012
   Google Scholar
• E Merck Patent Gmbh. Furopyridine derivatives. WO2013124025; 2013
   Google Scholar
• Signal Research Division. Aminotriazolopyridines and their use as kinase inhibitors. WO2010027500; 2010
   Google Scholar
• F Hoffmann-La Roche AG. Triazolopyridine compounds. WO2012163724; 2012
   Google Scholar
• Takeda Pharmaceutical Co., Ltd. Fused heteroaromatic pyrrolidinones as syk inhibitors. WO2011079051; 2011
   Google Scholar
• Takeda Pharmaceutical Co., Ltd. Substituted 6-aza-isoindolin-1-one derivatives. WO2012177714; 2012
   Google Scholar
• Gilead Sciences, Inc. Imidazopyridines syk INHIBITORS. WO2011112995; 2010
   Google Scholar
• F Hoffmann-La Roche AG. Imidazopyridazine compounds. WO2013064445; 2013
   Google Scholar
• Origenis GmbH. Pyrazolo[4,3-d]pyrimidines useful as kinase inhibitors. WO2012143144; 2012
   Google Scholar
• Origenis GmbH. Heterocyclic compounds as kinase inhibitors. WO2012143143; 2012
   Google Scholar
• F Hoffmann-La Roche AG. Thienopyrimidine compounds. WO2013104575; 2013
   Google Scholar
• F Hoffmann-La Roche AG. Thiazolopyrimidine derivatives. WO2012130780; 2012
   Google Scholar
• Abbott Laboratories. Furo[3,2-d]pyrimidine compound. WO2012048222; 2012
   Google Scholar
• IRM LLC. Compounds and compositions as syk kinase inhibitors. WO2011014795; 2011
   Google Scholar
• Endo Health Solutions, Inc. Pyrimido- pyridazinone compounds and use thereof. WO2013028818; 2013
   Google Scholar
• CrystalGenomics, Inc. Novel aminoquinazoline compound having a protein-kinase inhibiting action. WO2012044090; 2012
   Google Scholar
• Almirall Prodesfarma SA. Compounds as syk kinase inhibitors. EP02489663; 2012
   Google Scholar
• AB Science SA. Thiazole and oxazole kinase inhibitors. WO2011086085; 2011
   Google Scholar
• Dynamix Pharmaceuticals Ltd. Compositions and methods for modulating a kinase. WO2012172438; 2012
   Google Scholar
• Glaxo Group Ltd. Pyridinyl- and pyrazinyl -methyloxy - aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk). WO 2012123311; 2012
   Google Scholar
• IMC Biotechnology. Small molecule inhibitors of protein kinases. WO2011139295; 2011
   Google Scholar
• E Merck Patent Gmbh. Cyclic diaminopyrimidine derivatives. WO2013126132; 2012
   Google Scholar
• Abbott Laboratories. Novel tricyclic compounds. WO2011068899; 2011
   Google Scholar
• Abbott Laboratories. Novel tricyclic compounds. WO2012149280; 2012
   Google Scholar
• Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (Syk). WO2010147898; 2010
   Google Scholar
• Patterson H, Nibbs R, McInnes I, Siebert S. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clin Exp Immunol 2013
   Web of Science ®Google Scholar
• Sharman JP, Klein L, Boxer M, et al. Phase 2 trial of GS-9973, a selective syk inhibitor, in chronic lymphocytic leukemia (CLL) and non-hodgkin lymphoma (NHL) [abstract 1634]. 55th American Society of Hematology Meeting; 2013
   Google Scholar
• McAdoo SP, Tam FWK. Fostamatinib disodium. Drugs Future 2011;36(4):273
   PubMed Web of Science ®Google Scholar